Petros Pharmaceuticals的动态

Meet Momentum Clinical Research at #BIO2024. Book a One-on-One partnering meeting with Prof Richard Stubbs, Momentum's Chief Medical Officer at the BIO International Convention in San Diego, June 3-6. "The Australia and New Zealand region is the perfect setting for your clinical trials. Fast. Reliable. High Quality. Cost effective." "The ANZ region has long been an important player for the Pharma and Biotech industry and Momentum Clinical Research is set to take clinical trials in the region to a new level. Connect with me at BIO to discover what we can do for you." Book now: https://lnkd.in/eEDtKaAK Don't miss the opportunity to discover how Momentum Clinical Research can accelerate your research with our streamlined and integrated process across the largest network of clinical trial sites in Australia and New Zealand. Book a partnering meeting with Prof Richard Stubbs to discuss your specific research requirements. #momentumclinicalresearch #BIO2024 #clinicaltrials #drugdevelopment #biotech #partnering #CRO

More on VKTX - Viking Therapeutics Below is from JPM research department yesterday. Background - JPM held the Healthcare Conference last week and interviewed the CEO of Viking as well as the other big pharma companies noted below. I think they did a nice job getting to the heart of Viking's current situation when it comes to partnerships/buyouts. His assessment is Pfizer and Sanofi are options and Merck unlikely. Viking's CEO talked about numerous options as well but didn't seem to indicate clear cut ones (likely price). Read the below and compare it to the CEO's comments during the Q&A at the end of session (link is below after signing in). My take is that Viking has a ton of options and are determining the best course to pursue to maximize shareholder value. Which is likely why the Manufacturing announcement was delayed. JPM's comments "M&A/business development in the obesity/T2D space was a focus point at the JPM Conference with read throughs to both VKTX/GPCR. The landscape/prospect for deals overall appears fluid as various US/Euro pharma companies have expressed interest in entering/expanding their pipeline in this therapeutic class, but we think there clearly remains a debate/a wide gap on valuation. Generally, we see a preference from pharma for next-gen assets/MOAs, defined differently from company to company, and potential to create combination assets. At the conference the most incremental comments came from 1) MRK (looking for oral small molecules/ruling out oral peptides, open to injectables of differentiated assets but ruling out injectable amylin), 2) PFE (could have $10-$15bn of M&A dry powder, including for obesity assets, later in 2025, open to differentiated oral/injectable MOAs including amylin and ruled out GLP-1 mono agonists), and 3) SNY (open to obesity assets, preferably early/preclinical/ph1 assets that can contribute to revenue in the next decade). We think there is a reasonable case to make that many pharma companies could be active in the space, so we think VKTX/GPCR have abundant pathways to strategic partnerships. Big picture, 1) many pharma companies are looking for growth assets to offset significant LOE pressures late in the decade and 2030s, and in that light, 2) T2D/Obesity is likely to become the largest therapeutic market in history with estimates still rising (we forecast $200bn+ by 2030), and 3) VKTX/GPCR have some of the most advanced/derisked pipeline assets outside of LLY/Novo, and amylin programs entering human trials in late 2025 add pipeline optionality." https://lnkd.in/eGGb8BAb

Heading to this year’s AIChE Annual Meeting in San Diego? Send me a DM if you’re interested in attending Rescale’s lunch session on Digital Threads for Data & Process Traceability & Reproducibility in Drug Discovery! https://lnkd.in/gPY-JUVj ?? Rescale works with leading life sciences companies to build digital threads that transform pharmaceutical development by connecting teams and automating complex scientific workflows. ?? This session will showcase how a Fortune 500 customer harnessed Rescale and Nextflow to automate molecular and quantum dynamics analysis, dramatically reducing manual data management and accelerating drug development timelines. Let me know if you’re interested in attending! #AIChE #chemicalengineering #digitalthreads #drugdiscovery

Heading to this year’s AIChE Annual Meeting in San Diego? Send me a DM if you’re interested in attending Rescale’s lunch session on Digital Threads for Data & Process Traceability & Reproducibility in Drug Discovery! https://lnkd.in/ggs4wFha Rescale works with leading life sciences companies to build digital threads that transform pharmaceutical development by connecting teams and automating complex scientific workflows. This session will showcase how a Fortune 500 customer harnessed Rescale and Nextflow to automate molecular and quantum dynamics analysis, dramatically reducing manual data management and accelerating drug development timelines. Let me know if you’re interested in attending! #AIChE #chemicalengineering #digitalthreads #drugdiscovery

Automate your research at the MPS World Summit in Seattle, WA, from June 10-14. Swing by our booth to explore our automated microscope lineup featuring the CQ1, CQ3000, and CV8000. Whether you're from a small biotech, academic institution, or pharmaceutical company, our products enable fast, confocal live-cell imaging. Learn more about the Yokogawa CQ1, the ultimate tool for live cell high-content analysis! #YokogawaLifeScience #3dimaging #confocalmicroscopy #microscopy #fluorescence #drugdiscovery

LAST CALL TO REGISTER! Open your mind, expand your network, and discover the power of sharing at the 32nd Annual Sharing Conference. See you there! #SharingConference #Registertoday

Dear PDA - Parenteral Drug Association Members! Register for our next Virtual Meeting IG Pre-Filled Syringes Wednesday, June 19, 4:00-5:00pm CET Our Topic: Headspace Gas Ingress Methods for CCIT of Autoinjectors Together with Frank Bamberg, Alessandro Morandotti, Philippe Lauwers I welcome you to this virtual meeting. We discuss with Derek Duncan container closure integrity testing (CCIT) application for an assembled autoinjector. Current approaches involve disassembly of the device and CCIT of the primary container, but new methods using headspace gas ingress have been developed for non-destructive CCIT of assembled devices. These methods can generate data on empty devices, which can be used to build a dossier of robust CCI data for container closure integrity assurance. Log-in information for the meeting will be EMAILED to all our current IG members, so make sure you have joined the Interest Group. Connect with the https://lnkd.in/ei4R93cN and be part of the discussion!?

Welcome to Week 40 of 52 Weeks of WOW: Word of the Week Wednesdays Word of the Week: ATTENDEE REGISTRATION Attendee Registration: The pivotal process through which individuals sign up to participate in a conference, typically requiring the submission of personal and professional details. Why is this important? Attendee registration serves as the gateway to the conference, enabling organizers to manage logistics, allocate resources, and tailor the event experience to the needs and preferences of registered attendees. What does the planner need to do? Develop user-friendly registration platforms, establish clear registration policies and procedures, and provide prompt and responsive support to registrants to ensure a seamless registration experience. How can planners apply it? By implementing efficient and accessible registration systems, planners can streamline the registration process, maximize attendee engagement, and gather valuable data to inform event planning and management. Key takeaway: Attendee registration is the first step towards a successful conference experience, laying the groundwork for attendee engagement, networking, and knowledge exchange within the conference community. #52WeeksofWOW #MEDiC #MEDiCseries #pharma #biotech #medicalmeetings #mmp #eventsindustry #meetingsandevents #eventprofs #medcomms #medicalcommunications

As the start of EU-HTA draws closer, the spotlight on changes in drug assessment processes intensifies. ?? How different are France and Germany in their assessments of newly launched drugs? Are you familiar with the nuances? Join us this May as we explore the distinct paths of these two leading EU nations in our latest co.value? market access quiz. Dive into the similarities, and differences and test your knowledge! ?? Start the quiz now: https://lnkd.in/e7WCExiQ #EUHTA #MarketAccess #Pharmaceuticals #HealthcareReform #France #Germany

As a matter of update to meeting with Sever Pharma Solutions (me) at BIO 2024, they have provided an easy way to organize a meeting. Let's meet!! Click below to send Sever Pharma Solutions?a meeting request in the BIO partnering system!?#BIO2024 https://lnkd.in/eSuwrVS9 #Hotmeltextrusion #MeltExtrusion #Longactingimplants #Soubilityenhancement #Prefilledsyringes #HPAPIformulation